Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC)
Brief Summary: This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.


Options:
A: Arm Label: talazoparib; Type: EXPERIMENTAL; Interventions: Drug: talazoparib | Intervention Type: DRUG; Name: talazoparib; Assigned to Arm(s): talazoparib
B: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Physician's choice chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physician's choice chemotherapy | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Physician's choice chemotherapy; Assigned to Arm(s): Physician's choice chemotherapy
C: Arm Label: Veliparib with Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Temozolomide | Arm Label: Placebo with Carboplatin and Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Carboplatin, Drug: Paclitaxel | Arm Label: Veliparib with Carboplatin and Paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with Carboplatin and Paclitaxel | Intervention Type: DRUG; Name: Veliparib; Assigned to Arm(s): Veliparib with Carboplatin and Paclitaxel, Veliparib with Temozolomide | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo with Carboplatin and Paclitaxel, Veliparib with Carboplatin and Paclitaxel | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Veliparib with Temozolomide | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo with Carboplatin and Paclitaxel, Veliparib with Carboplatin and Paclitaxel
D: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Paclitaxel, Drug: Carboplatin, Drug: Veliparib | Arm Label: Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Placebo, Drug: Doxorubicin, Drug: Paclitaxel | Arm Label: Arm B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Paclitaxel, Drug: Carboplatin, Drug: Placebo | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm C | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Veliparib; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm B, Arm C

Answer: D